07 January 2015
Vol 7, Issue 269

About The Cover

Cover image expansion

ONLINE COVER Adding to the Armamentarium. Mycobacterium tuberculosis (pictured), the bacterium that causes tuberculosis, is becoming increasingly resistant to the standard regimen of frontline drugs, including isoniazid. A new class of compounds, the 4-hydroxy-2-pyridones, block the same therapeutic target as isoniazid, the mycobacterial enoyl reductase InhA, but do so via a different mechanism Manjunatha et al. The lead compound of this class prevented bacterial growth in two mouse models of tuberculosis and was also active against different clinical isolates of multidrug resistant M. tuberculosis, suggesting that further development of this drug class is warranted. [CREDIT: SPL/SCIENCE SOURCE]